Discover Great Companies Discover Great Clients
Popularity  1万   |   Followers  7   |   Likes  17   |   Feedback  5 Claim this company

An innovative biopharmaceutical company focused on disease treatment a

No.193 Qixia District Popularity Ranking Nanjing Jiangsu No.8 Biopharmaceuticals Technology No.15 Pharmaceutical Contracts R&D No.83 Pharmaceutical Technology No.97 Lin Chuang Yi Xue Healthcare Technology CRO Services Zhong Liu Xue Han Jian Bing Yao Products Han Jian Yao Yi Yao Ke Xue Pharmaceutical Analysis Biopharmaceuticals R&D 科技型中小企业 国家科技型中小企业 省级高新技术企业 省科技型中小企业 发明专利 市级创新型中小企业
More

Company Overview

  • Nature: Joint Venture Size: 100-499 employees Founded: 9年
  • Industry: Pharmaceutical/Bioengineering
  • Full name: Nanjing Bioheng Biotech Co., Ltd.。

Development Stage

  • Stage: A轮 , 1亿人民币。
  • Ranking: Ranked #8 in Nanjing Biopharmaceuticals Technology Company by popularity
  • Honors: 科技型中小企业 国家科技型中小企业 According to algorithm

About the Company

[Summary] An innovative biopharmaceutical company focused on disease treatment a

Bioheng is a clinical-stage company focused on the development and clinical translation of allogeneic "off-the-shelf" universal CAR-T therapies. Founded in 2017, the company aims to develop a "world-leading" allogeneic cell therapy platform and products to address challenging and unmet clinical needs.

In March 2022, Bioheng's CTA101 universal CAR-T cell therapy received Investigational New Drug (IND) approval.

In June 2021, Bioheng's CD7-targeted universal CAR-T cell therapy received Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration (FDA) for the treatment of T-cell acute lymphoblastic leukemia (T-ALL). This product is based on Bioheng's independently developed universal CAR-T technology platform, ANSWER®. The company is advancing global clinical trials of this promising product pipeline.

Based on the ANSWER® platform, Bioheng is actively developing multiple universal CAR-T product pipelines. These programs have demonstrated strong and durable allogeneic CAR-T cell persistence, showing strong potential in autoimmune and oncology fields.

We are always making our utmost efforts to fill unmet clinical needs.
Company website: *

Expand
Information is aggregated from the web and may not be exact. For reference only.
Information incorrect? Claim this company to edit

Bioheng Financing History (1 rounds)

Manage
A轮
Capital Market Favor
Latest Financing Round
  • Date: ?
  • Amount: 1亿人民币
  • Investor: 德诚资本

Bioheng honors, qualifications & industry associations

Tags are labelled based on keyword text matching analysis and may be related to the company. For reference only.

Business Registration

Provided by

Operating Status: 开业
Registered Capital: 526.3158万(元)
Legal Representative: 任江涛
Date Established:
Credit Code: 91320113MA1NMP438D
Registered Address: 南京市江北新区探秘路73号树屋十六栋B1-2栋

People who follow Bioheng also follow

Bioheng Competitors (Similar Companies)

“Let everyone have trust and expectation in Baili because of health!”
生物科技/生物工程 试剂 生物试剂 体外诊断试剂
制药/药业 药物研发 生物制药 医药
失效分析 汽车检测 环境影响评价 环境监测
生物科技/生物工程 干细胞 细胞治疗 医药
环保/节能 研发 环境科学 环境影响评价
大健康 膳食补充剂 女性健康 研发
生物医药 医药 医疗科技 医药科技
检验 检测 检测认证 检测技术
制药/药业 医药 水剂 生物制药
新材料 能源 化工/化学 橡胶
健康科技 医疗健康

Discover Great Companies, Discover Great Clients

南京公司名录 南京“Qixia District”公司名录 南京“医疗科技”公司名录 南京“临床医学”公司名录 南京“医药科技”公司名录 南京“医药合同研发”公司名录 南京“生物医药科技/技术”公司名录 附近的公司

Report

*Reason:

Radical political or ideological topics
Advertising or spam
Pornographic or vulgar content
Obscene language or personal attacks
Other

Congratulations, submitted successfully!

Your edit is under review. You will be notified by email within 1 business day.

Submission failed.

Followed successfully. We'll notify you of any company updates.

Help others learn about this company, add my impression of this company»

Log in with the following accounts to save your follows

Followed successfully, we'll notify you of any company updates